The company Regeneron presented a clinical study where a dose of a REGEN-COV antibody reduces the chance of an uninfected person becoming infected with the virus by 81.6% for up to eight months after taking the drug.
This study was a phase 3 and included people who came in contact with a positive case in the previous four days. The Doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Panos Malandrakis, Giannis Danasis and Thanos Dimopoulos (Rector of EKPA) summarize the relevant announcement. None of the patients receiving the antibody was treated, while six patients were treated in the placebo group. None of the patients in the study ended up.
The FDA approved the antibody in patients with mild / moderate disease and as a preventative treatment in those exposed to the disease. This treatment is considered very useful for those who are immunosuppressed and have a reduced antibody response to the vaccine. Now the goal is to create drugs other than the vaccine, such as the Pfizer and Merck pills that reduce mortality in mild to moderate disease compared to placebo. Based on these data, it is considered possible to extend the approval of REGEN-COV to individuals who have not been exposed to the virus but are immunosuppressed.
.
